It has been about a month since the last earnings report for Myriad Genetics (MYGN). Shares have added about 8.7% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Myriad due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.
Myriad Genetics Reports Break-Even Earnings for Q3
Myriad Genetics, Inc.reported break-even earnings in the third quarter of 2025 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The company reported 6cents earnings per share in the year-ago quarter.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP net loss was 29 cents per share in the third quarter compared to the prior-year quarter’s loss of 24 cents.
MYGN’s Q3 Revenues
Total revenues decreased 3.6% year over year to $205.7 million. The figure surpassed the Zacks Consensus Estimate by 0.24%.
Myriad Genetics’ 2025 Guidance
For 2025, the company forecasts revenues in the range of $818-828 million. The Zacks Consensus Estimate for MYGN’s revenues currently stands at $821.9 million.
Meanwhile, adjusted earnings per share are now expected between a loss of 2 cents and earnings of 2 cents. Going by the Zacks Consensus Estimate, earnings are expected to be 1 cent in 2025.
How Have Estimates Been Moving Since Then?
Since the earnings release, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -7.89% due to these changes.
VGM Scores
At this time, Myriad has a great Growth Score of A, a score with the same score on the momentum front. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Interestingly, Myriad has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Biogen Inc. (BIIB), a stock from the same industry, has gained 20.7%. The company reported its results for the quarter ended September 2025 more than a month ago.
Biogen reported revenues of $2.53 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.81 for the same period compares with $4.08 a year ago.
For the current quarter, Biogen is expected to post earnings of $1.73 per share, indicating a change of -49.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -14.1% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Biogen. Also, the stock has a VGM Score of B.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
